DiaMedica Therapeutics (DMAC) vs Eikon Therapeutics (EIKN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DiaMedica Therapeutics is the larger company by market cap ($431.9 million vs $406.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | EIKN |
|---|---|---|
| Share price | $8.01 | $7.50 |
| Market cap | $431.94M | $406.24M |
| 1-day change | +0.25% | -0.53% |
| YTD return | +0.38% | — |
| 1-year return | +16.47% | — |
| 5-year return | +94.88% | — |
| EPS (TTM) | $-0.72 | $-8.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.42 | $17.40 |
| 52-week low | $5.25 | $7.02 |
| Distance from 52-week high | -23.12% | -56.90% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +93.51% | +228.00% |
| Average volume | 177.22K | 497.76K |
| Shares outstanding | 53.93M | 54.17M |
| Employees | 35 | 384 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
DMAC vs EIKN FAQ
Which is bigger, DiaMedica Therapeutics or Eikon Therapeutics?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $431.94M compared with $406.24M for Eikon Therapeutics (EIKN).
Are DiaMedica Therapeutics and Eikon Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for DiaMedica Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Eikon Therapeutics.